PANTORC ® Pantoprazole

PANTORC ® is a Pantoprazole-based drug.

THERAPEUTIC GROUP: Antireflux - Antiulcer - Acid pump inhibitors

Indications PANTORC ® Pantoprazole

PANTORC ® is used both as a preventive pharmacological treatment of gastric and duodenal ulcers induced by the prolonged use of non-steroidal anti-inflammatory drugs, and as a therapeutic treatment of symptoms associated with gastroesophageal reflux.

PANTORC ® Mechanism of Action Pantoprazole

The pantoprazole contained in PANTORC ® represents an active ingredient belonging to the pharmacological category of proton pump inhibitors, with advantageous pharmacokinetic characteristics compared to the more common omeprazole.
In fact, once taken orally, pantoprazole is rapidly absorbed at the duodenal level, reaching the maximum plasma concentration in just 2 hours, with a bioavailability that is around 77% of the total dose taken, therefore significantly higher than 30. % of omeprazole.
From a pharmacodynamic point of view, however, the mechanism of action of this active principle remains almost unchanged, being able to act selectively on the H + / K + ATPase pump, expressed by the parietal cells of the stomach, thus inhibiting both basal and hormone-induced acid secretion. such as gastrin or histamine.
It is therefore evident that his prolonged use of this drug will be accompanied by a significant increase in the blood concentrations of gastrin, fortunately without clinically evident repercussions.
Once its action is over, after a very rapid half-life, the drug is mainly eliminated through the renal pathway.

Studies carried out and clinical efficacy

1. PANTOPRAZOLE AND GASTROESOPHAGEOUS REFLUX DISEASE

MMW Fortschr Med. 2010 Apr 8; 152 Suppl 1: 21-9.

Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease.

Gillessen A.

Treatment with pantoprazole has proved particularly effective in treating the symptoms associated with gastroesophageal reflux, resulting in a reduction in cases of heartburn, acid secretion, abdominal pain and dyspepsia without particular side effects in a single week of treatment.

2. PANTOPRAZOLE AND GASTROINTESTINAL HEMORRAGES

J Crit Care. 2011 Jan 25.

Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes.

Wu H, Jing Q, Wang J, Guo X.

Patients with acute coronary syndrome have a high risk of developing gastrointestinal bleeding. In these patients, the administration of 40 mg of pantoprazole per day for 7 days has been shown to be useful in significantly reducing the incidence of this adverse reaction, without particular side effects.

3. CROSS REACTIVITY "BETWEEN PROTONIC PUMP INHIBITORS

Clin Drug Investig. 2010; 30: 559-63.

Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole.

Gouraud A, Vochelle V, Descotes J, Vial T.

The cross reactivity between different proton pump inhibitors was ascertained in this clinical case, in which a 60-year-old man experienced neutropenia both after taking omeprazole and pantoprazole after about 1 year. These data are important to underline. the presence of cross reactivity between different proton pump inhibitors.

Method of use and dosage

PANTORC ® gastro-resistant tablets of 20-40 mg pantoprazole:
both in the treatment of symptoms associated with gastro-oesophageal reflux and in the prevention of ulcers and esophagitis, the effective daily dose is 20 mg taken preferably in the morning with a glass of water.
In general, the remission of symptoms is observed in 2-4 weeks of treatment, at the end of which, a one-off intake could be used following the reappearance of symptoms.
Dosage variations could be foreseen in particular categories of patients at risk, and always under strict indication of your doctor.

PANTORC ® Pantoprazole Warnings

Before taking PANTORC ®, the doctor should carry out a "careful clinical evaluation of the patient, aimed at excluding the malignant origin of the pathologies of the gastrointestinal tract, so that the therapeutic action of the drug, capable of masking some particularly important symptoms , do not delay its diagnosis.
The reduction in the acid content of the stomach, which is very important following a prolonged intake of pantoprazole, could lead to a reduction in the absorption of vitamin B12, with the onset of related symptoms.
The administration of PANTORC ® should take place with particular care in patients with impaired renal and hepatic function.

PREGNANCY AND BREASTFEEDING

The studies currently present in the literature, statically insignificant, do not allow to fully characterize the safety profile of pantoprazole, when taken during pregnancy.
Therefore we do not recommend the use of PANTORC ® during pregnancy and the subsequent lactation period.

Interactions

As is known, pantoprazole is metabolized by the cytochrome p450 system, also involved in the metabolism of high active ingredients such as carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and contraceptives .
In light of these data, possible interactions could alter the normal pharmacokinetic properties of the above compounds, with particular importance for anticoagulants, for which continuous monitoring of the prothrombin time would be necessary.
Furthermore, the concomitant intake of atazanavir and pantoprazole could result in a significant reduction in the absorption of atazanavir, which is achieved due to the acid content of the stomach.

Contraindications PANTORC ® Pantoprazole

PANTORC ® is contraindicated in patients with known hypersensitivity to the active substance or to one of its excipients. Given the possibility of cross reactivity, it would be advisable to avoid taking the drug even in case of hypersensitivity to compounds analogous to pantoprazole.

Undesirable Effects - Side Effects

Clinical trials and post-marketing monitoring have shown some particularly frequent side effects, such as headache, drowsiness and dizziness, abdominal pain, nausea, vomiting, diarrhea, constipation and flatulence, following the intake of PANTORC ®
Cases of onset of liver, kidney, haematological and skin damage, which quickly disappeared once therapy was discontinued, were rarer.

Note

PANTORC ® a drug that can only be sold under medical prescription.

The information on PANTORC ® Pantoprazole published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.